KDR and gastroesophageal junction adenocarcinoma: Ramucirumab, a humanized monoclonal antibody against VEGFR2, combined with paclitaxel has been approved by the US Food and Drug Administration (FDA) for the treatment of advanced esophagogastric adenocarcinoma (EAC) (Fuchs et al., 2014; Wilke et al., 2014; Young et al., 2015).